Patients with Alport syndrome progressively lose renal function as a result of defective type IV collagen in their glomerular basement membrane. In mice lacking the ␣3 chain of type IV collagen (Col4A3 knockout mice), a model for Alport syndrome, transplantation of wild-type bone marrow repairs the renal disease. It is unknown whether cell-based therapies that do not require transplantation have similar potential. Here, infusion of wild-type bone marrow-derived cells into unconditioned, nonirradiated Col4A3 knockout mice during the late stage of disease significantly improved renal histology and function. Furthermore, transfusion of unfractionated wild-type blood into unconditioned, nonirradiated Col4A3 knockout mice improved the renal phenotype and significantly improved survival. Injection of mouse and human embryonic stem cells into Col4A3 knockout mice produced similar results. Regardless of treatment modality, the improvement in the architecture of the glomerular basement membrane is associated with de novo expression of the ␣3(IV) chain. These data provide further support for testing cell-based therapies for Alport syndrome.
Alport syndrome is characterized by the progressive development of glomerulonephritis associated with the loss of ␣3␣4␣5 type IV collagen protomer in the glomerular basement membrane (GBM). 1 The type IV collagen chain composition in the GBM is critical to the maintenance of the glomerular filtration. 2, 3 Genetic mutations in ␣3, ␣4, or ␣5 (IV) collagen chains result in the ablation of the obligatory posttranslational assembly of ␣3␣4␣5(IV) protomer, which leads to renal disease in patients with Alport syndrome. 2,4 -7 The engineered genetic mutation in the COL4A3 gene [encoding for ␣3(IV) chain; the Col4A3 knockout mouse] provides us with a mouse model that closely recapitulates the human disease. 8, 9 Col4A3 knockout mice develop progressive glomerulonephritis associated with the loss of the GBM ␣3␣4␣5(IV) protomer and die as a result of renal failure. Importantly, the progression of the disease in mice varies with respect to their genetic background. Col4A3 knockout mice, on the 129Sv genetic background, progress more rapidly and die at approximately 13 wk of age in comparison with Col4A3 knockout mice on the C57BL/6 background, which die of renal failure at approximately 22 wk of age in our laboratory. It is suggested that the difference in disease progression between these two strains of mice results from the compensatory effect of ␣5␣6␣5(IV) protomer in the GBM of Col4A3 knockout on C57BL/6 genetic background, which is negligible when this mutation is on the 129Sv background. 10 This modifying effect suggests that type IV collagen protomer composition is critical for GBM function and suggests that modulating GBM type IV composition, by providing the missing chain collagen to the GBM of Col4A3 knockout mice, could theoretically slow down or halt the progression of the renal disease.
Previous preclinical studies demonstrated that de novo production of ␣3(IV) collagen in Col4A3 knockout mice that received a transplant of wild-type (WT) bone marrow (BM) is associated with significant improvement in renal function. 11, 12 We and others have shown that BM-derived cells specifically target the diseased glomeruli and allow for the deposition of ␣3(IV) chain, which results in the restoration of the ␣3␣4␣5(IV) protomer in the GBM. 11, 12 These results suggest that BM-derived cells provide a therapeutic benefit to the Col4A3 knockout mice. Nonetheless, a disease-modulating effect of total body irradiation on the progression of the kidney disease was recently suggested in Col4A3 knockout mice on the 129Sv genetic background. 13 Unlike the human disease, kidney disease progression in Col4A3 knockout mice involves significant immune infiltration; therefore, a case can be made that total body irradiation and subsequent BM transplantation in Col4A3 knockout mice could modulate disease progression by diminishing renal immune infiltration. Our previous report demonstrated that lymphocyte ablation improves renal interstitial fibrosis in Col4a3/Rag-1 double-KO mice on C57BL/6 background 16 as a result of diminished interstitial infiltrates. Recently, Katayama et al. 13 provided evidence for an increase in the survival of Col4A3 knockout mice on 129Sv background, associated with improvement in renal function and histologic findings after total body irradiation; however, that study does not conclusively negate the specific therapeutic potential of BM-derived cells in the recovery of the renal phenotype.
A better understanding of the cell-based therapy in Col4A3 knockout mice is critical for future clinical development of this therapeutic strategy for patients with Alport syndrome. Here we provide a critical evaluation of a cellular process in the therapy of Col4A3 knockout mice. Our experiments unequivocally demonstrate that cell-based therapy is a viable option in the treatment of Alport syndrome. Figure 1 ). Furthermore, our results show that both syngeneic and nonsyngeneic BM transplantations improve proteinuria and provide the missing chain of type IV collagen in Col4A3 knockout mice on the 129Sv genetic background (see supplemental supporting text and Supplemental Figure 2 ).
RESULTS

BM Transplantation in
Multiple Infusions of WT BM Cells Rescue the Renal Phenotype of COL4A3KO Mice
Our analysis of mice with Col4A3 knockout BM transplant reveals that BM cells with the WT allele rather than with the KO allele of the COL4A3 gene provide significant improvement in renal function and histology (Supplemental Figure 1) . To provide evidence that the observed improvement in the renal disease is dependent on a BM-derived cell, we investigated whether BM cell infusions in non irradiated Col4A3 knockout mice on the C57BL/6 genetic background provide similar phenotypic improvement. We began BM infusions in a littermate cohort of eight Col4A3 knockout mice ( Figure 1A ). Col4A3 knockout mice on the C57BL/6 genetic background develop progressive glomerulonephritis and die from renal failure between 19 and 25 wk of age. We chose specifically to evaluate littermate Col4A3 knockout mice, which present with similar disease progression rate. When the first mouse in one of the cohort succumbed to renal failure at 19 wk of age, we began BM infusions and continued infusions during the course of the next 3 wk. After 3 wk of repeated BM infusions, all mice were killed when another Col4A3 knockout mouse, which received Col4A3 knockout BM infusion at 20 wk, died as a result of renal failure ( Figure 1A) .
Urine albumin-creatinine ratio improved in Col4A3 knockout mice infused with WT BM at 20 wk, in contrast with mice infused with Col4A3 knockout BM, and a significant difference was noted at 21 and 22 wk of age, halfway during the course of the BM infusions ( Figure 1B ; Table 1 ) . Histologic findings also revealed significant improvement in glomerular sclerosis, with an increase in percentage of normal glomeruli, tubular atrophy, and relative interstitial volume of Col4A3 knockout mice infused with WT BM in comparison with mice infused with Col4A3 knockout BM (Figure 1 , C through G; Table 1 ). These results therefore suggest that the BM-derived cells in Col4A3 knockout mice infused with WT BM are responsible for the observed improvement in the glomerular and tubular compartments rather than a mere radiation effect.
The phenotypic rescue observed in Col4A3 knockout mice infused with WT BM cells was associated with changes in GBM type IV collagen composition. The missing ␣3(IV) collagen chain was expressed in the GBM of Col4A3 knockout mice infused with WT BM mice, whereas it remained absent in mice infused with Col4A3 knockout BM ( Figure 1J ). The expression of ␣3(IV) collagen chain in GBM of Col4A3 knockout mice infused with WT BM was associated with a noticeable increase in ␣5(IV) collagen deposition in these mice in contrast with mice infused with Col4A3 knockout BM at 20 wk( Figure 1J ). Our immunostaining data thus suggest that BM-derived cells alter the GBM type IV collagen composition in Col4A3 knockout mice, likely resulting in improved GBM stability and glomerular filtration. Reverse transcriptase-PCR (RT-PCR) for COL4A3 expression and Western blot analyses of kidney extracellular matrix (ECM) extract revealed ␣3(IV) collagen expression in Col4A3 knockout mice infused with WT BM at 20 wk, in contrast with mice infused with Col4A3 knockout BM ( Figure 1, H and I) . Furthermore, Col4A3 knockout mice infused with WT BM presented with increased levels of ␣5(IV) chain ( Figure 1I ). Taken together, these results demonstrate that WT BM-derived cells allow for significant improvement of renal histologic findings associated with changes in the GBM type IV collagen composition, de novo expression of the missing ␣3(IV) collagen chain, and increased ␣5(IV) collagen expression.
In our previous BM transplantation study, 11 we demonstrated that BM derived-cells localized to the kidney in Col4A3 knockout mice infused with WT BM at 20 wk. We wondered Immunolabeling of mouse ␣3(IV) and ␣5(IV) collagen in kidney glomeruli of Col4A3 knockout mice that received BM transplant from Col4A3 knockout and mice that received BM transplant from WT mice mice; secondary FITC-conjugated antibody was used in negative control (NC). (K) Representative transmission electron microscopy images from Col4A3 knockout mice that received BM transplant from Col4A3 knockout mice and mice that received BM transplant from WT mice at 23.5 wk of age. P, podocyte; FP, foot processes. GBM is partly underlined. (L) Genotyping PCR amplification of Col4a3 WT (1000-bp product) and Col4A3 knockout (850-bp product) gene from genomic DNA extracted from the BM of Col4A3 knockout mice that received BM transplant from Col4A3 knockout mice, Col4A3 knockout mice that received BM transplant from WT mice, Col4A3 knockout, WT, and Col4A3 heterozygote (HET). NC, no template control. *P Ͻ 0.05; **P Ͻ 0.01. Magnifications: ϫ100 and ϫ400 in C; ϫ400 in J.
whether the homing of the infused BM cells to the recipient's BM was a prerequisite for subsequent homing to the inflamed kidney of the Col4A3 knockout mice. We analyzed the genotype of the BM cells harvested from Col4A3 knockout recipients upon completion of the treatment. We did not detect the WT copy of the COL4A3 gene, suggesting that BM-infused cells do not home to the recipient's BM ( Figure 1L ). These results suggest that recruitment of BM-derived cell to the kidney does not require previous homing to the recipient's BM. Finally, electron microscopy imaging of the GBM revealed restored GBM architecture in Col4A3 knockout mice infused with WT BM at 20 wk, with decreased splitting and thickening of the GBM when compared with the mice infused with Col4A3 knockout BM ( Figure 1K ), consistent with renal function and histologic improvement. In addition, BM infusions increased the lifespan of Col4A3 knockout mice in comparison with mice infused with Col4A3 knockout BM, with death of four out of five mice infused with Col4A3 knockout BM at 26.5 wk of age, a time point at which five out of five mice infused with WT BM at 20 wk were still alive (Supplemental Figure  3D ). Finally, we tested whether a single injection of WT unfractionated BM cells in unconditioned Col4A3 knockout recipients (at an earlier time point in the disease progression) could provide the missing chain of type IV collagen. Our results indicated a single injection of WT BM cells into 8-wk-old Col4A3 knockout mice was sufficient to provide the missing chain of type IV collagen in kidney GBM, detected by RT-PCR and Western blot analyses, 12 wk after the single infusion (see supplemental supporting text and Supplemental Figure 3 ).
Simple Blood Transfusion into Col4A3 Knockout Mice Improves Renal Function and Histologic Findings
We next evaluated the feasibility of long-term blood exchange, via parabiotic pairing, in inducing therapy in the Col4A3 knockout mice (Supplemental Figure 3E ). Western blot analyses of kidney ECM proteins revealed the expression of ␣3(IV) collagen in the recipient parabiont mouse (Supplemental Figure 3F ). We then asked whether simple blood transfusions could rescue the renal phenotype in Col4A3 knockout mice. We used green fluorescence protein-positive (GFP ϩ ) transgenic mice as blood donors. Initially, we transfused 8-wk-old Col4A3 knockout mice and sacrificed the recipient mice at 12.5 wk of age ( Figure 2A ). Morphometric analyses of histologic findings ( Figure 2B ) revealed a statistically significant improvement in glomerular sclerosis, tubular atrophy, and interstitial volume ( Figure 2 , C through E; Table 2 ). Renal function tests revealed an improvement of the renal phenotype in agreement with the histologic findings. Col4A3 knockout mice transfused at 8 wk with blood from WT mice presented with significantly lower serum blood urea nitrogen (BUN) levels, similar to that of WT control mice ( Figure 2F ; Table 2 ). Similarly, urine albumin-creatinine ratio was significantly lower in transfused Col4A3 knockout mice in comparison with untreated Col4A3 knockout mice ( Figure 2G ; Table 2 ). Concurrently, we also transfused 23.5-wk-old Col4A3 knockout mice with blood harvested from GFP ϩ or from Col4A3 knockout donor mice ( Figure 2H ). In such late-stage blood transfusion rescue experiment, Col4A3 knockout mice received transfusions when they developed end-stage renal failure. Importantly, the control Col4A3 knockout blood was harvested from young nonanemic Col4A3 knockout donor mice (6 wk of age). Recipients received two to three blood transfusions per week for 3 wk (the volume of each transfusion was between 200 and 300 L). Histologic findings showed that Col4A3 knockout mice with blood harvested from GFP ϩ mice presented with statistically significant improvement in glomerular sclerosis, tubular atrophy, and interstitial volume in contrast with mice transfused with blood from Col4A3 knockout mice ( Figure 2 , I through L; Table  2 ). Renal function tests indicated a statistically significant improvement in proteinuria (urine albumin-creatinine ratio) and BUN in the Col4A3 knockout mice transfused with blood harvested from GFP ϩ micemice, in comparison with mice transfused with blood harvested from Col4A3 knockout mice ( Figure 2 , M and N; Table 2 ). Western blot analyses of kidney ECM proteins revealed expression of ␣3(IV) and ␣4(IV) type IV collagen chains in WT and Col4A3 knockout mice transfused at 8 wk with blood from WT mice, but such expression in Col4A3 knockout (KO) control mice was not observed ( Figure 3A) . Electron microscopy imaging of GBM from WT, Col4A3 knockout, and Col4A3 knockout mice transfused at 8 wk with blood from WT indicated a We tested the hypothesis that such therapeutic cells may derive from the hematopoietic compartment of the BM. A previous study using BM-derived mesenchymal stem cells in COL4A3KO mice suggested that mesenchymal stem cell therapy did not lend itself to the synthesis of the missing chain of type IV collagen 14 ; therefore, we focused our attention on the hematopoietic compartment. We asked specifically whether lymphocytes and macrophages are among the therapeutic cells in the cellbased therapy in Col4A3 knockout mice. Using specific hematopoietic cell lineage-deficient mice in BM transplant studies in Col4A3 knockout mice, our results indicate that B/T lymphocytes and monocytes/macrophages are not required for the emergence of the missing ␣3(IV) in the GBM of Col4A3 knockout mice that receive BM transplant (Table 3 , supplemental text and Supplemental Figure 4) .
In an effort to expand our understanding of the cell-based therapy in the Col4A3 knockout mouse model and establish specificity, we questioned whether pure cultures of mouse embryonic stem cells (mESCs) could offer a therapeutic benefit when transplanted into Col4A3 knockout mice by providing BASIC RESEARCH www.jasn.org the missing ␣3 chain of type IV collagen. Our preliminary data indicated that mESCs can differentiate in vitro into renal progenitor cells expressing podocyte markers, including nephrin and podocin (Supplemental Figure 7N) . These in vitro findings prompted our investigation of the therapeutic capacity of mESCs in Col4A3 knockout mice. Our results demonstrated homing of the undifferentiated mESCs to the Col4A3 knockout recipient kidney, unlike the differentiated mESCs, was associated with a statistically significant improvement in renal function and histologic findings and improvement in GBM architecture (see supplemental text and Supplemental Figures  5 through 7) . Importantly, the synthesis of the missing ␣3 chain of type IV collagen after mESC injections resulted in the recovery in the ␣3␣4␣5 IV collagen protomer (see supplemental text and Supplemental Figure 6 ) ( Table 4 ). In addition, our studies using human embryonic stem cells (hESCs) in Col4a3/ Rag-1 double-KO mice demonstrate an expression of the missing chain of type IV collagen (Supplementary Text and Supplementary Figure 7 ) produced by the hESCs and incorporated within the mouse GBM type IV collagen network. These results support previous studies which demonstrate that human ␣ chain of type IV collagen can form chimeric protomers in the Col4A3 knockout mice.
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DISCUSSION
A better understanding of the therapeutic potential of BMderived cells and stem cells in the rescue of the renal phenotype in Col4A3 knockout mice is critical for potential testing in the clinic. A recent research report and an editorial by 22 scientists questioned the rationale of cell-based therapy for Alport syndrome and suggested that more studies are required to validate further the potential of such therapeutic option in preclinical studies in mice. 13, 15 Here, we oblige with more experiments and mechanistic approaches aimed to address the potential of a cell-based therapy in the Col4A3 knockout mice.
Whereas irradiation alone may offer a small benefit in the recovery of renal function in the Col4A3 knockout mice, a significant benefit in the recovery of renal function is observed only when WT BM cells are provided along with irradiation. In addition, nonirradiated Col4A3 knockout mice that receive multiple infusions of WT BM cells demonstrate significant improvement in renal function and incorporation of the missing chain of type IV collagen in the GBM. Simple blood transfusion and injection of pure cultures of undifferentiated mouse embryonic stem cells into Col4A3 knockout mice also provide significant protection from renal disease and are also associated with incorporation of the missing ␣3 chain of type IV collagen into the GBM of Col4A3 knockout. These mechanistic studies provide unequivocal evidence that irradiation is not required for realizing the therapeutic benefit of cell-based therapy. Moreover, the use of undifferentiated mESCs demonstrated that stem cells possess the capacity to improve renal function and generate new collagen chains in the Col4A3 knockout mice, whereas the differentiated mESCs or cultured podocytes did not provide such benefit, further highlighting the notion that injury responses can educate undifferentiated stem cells to provide relief to the damaged kidney by repairing the GBM; however, the risk for teratoma formation in mESCtreated Col4A3 knockout mice precludes the development of therapy using these cells. We therefore attempted to better characterize the BM-derived therapeutic cell population in Col4A3 knockout mice that received a transplant. In our BM transplant studies, mature lymphocytes and monocytes seemed to play a limited role in the rescue of the renal pathology in Col4A3 knockout mice. Despite the significant protection of the tubulointerstitial compartment after ablation of mature B and T lymphocytes, 16 this improvement did not result in an increase in the lifespan of Col4a3/Rag-1 DKO in comparison with Col4A3 knockout mice. Ablation of B and T cells and monocytes with the WT allele for COL4A3KO in the reconstituted BM did not preclude the expression of the missing chain of type IV collagen in Rag-1KO or CD11bKO BMtransplanted Col4A3 knockout mice. Although our findings indicate that these mature immune cells are not required for the de novo deposition of ␣3(IV) chain in Col4A3 knockout mouse GBM, the identity of the therapeutic cell population in the BM remains unclear. Our experiments with ESCs, however, suggest that cell plasticity is desirable property for the synthesis of type IV collagen in the GBM in the context of a cell-based therapy in Col4A3 knockout mice. The BM-derived therapeutic cell population may possess features shared by mESCs, namely cell plasticity and totipotency. Indeed, differentiated mESCs did not provide Col4A3 knockout mice with a therapeutic advantage, thus suggesting that preserving the plu- ripotency and cellular plasticity of mESCs is a prerequisite to successful cell-based therapy in Col4A3 knockout mice. Our experiments, however, lead us to conclude that B and T cells as well as macrophages are dispensable to restoring the renal phenotype in Col4A3 knockout mice, thereby supporting the notion that cell-based therapy is an attractive option for development in the clinic. Keeping in mind the challenges of potential clinical trial designs, we also evaluated the relative efficiency of syngeneic versus nonsyngeneic BM transplant in Col4A3 knockout mice on 129Sv genetic background. In contrast to the analysis of BM transplant therapy in Col4A3 knockout mice on 129Sv genetic background by Katayama et al., 13 our results indicate that BM transplantation significantly improves proteinuria status, in both syngeneic and nonsyngeneic transplant settings. Our results contradict the experiments published by Katayama et al., 13 and such differences could partly be explained by the timing of the therapy and method of BM transplantation. Interestingly, our results demonstrate a relative difference in the renal function recovery between syngeneic and nonsyngeneic BM transplantations, possibly highlighting an inherent modifying effect provided by BM cells from the C57BL/6 donor mice.
Our results demonstrate that a cell carrying the WT allele for the missing ␣3(IV) chain in Col4A3 knockout mouse recipient can synthesize the missing chain, which subsequently assembles into protomers found in the GBM type IV collagen network. The recovered ␣3(IV) chain combined with its ␣4 and ␣5(IV) binding partners, and the newly assembled ␣3␣4␣5(IV) protomer dramatically improves the GBM architecture and reverses the renal phenotype in these mice. Our results suggest that a relatively small amount of the newly synthesized ␣3(IV) chain in the Col4A3 knockout mouse leads to a significant increase in ␣5(IV) chain expression in the GBM, and together this change in the chain composition in the GBM type IV collagen network brings about the dramatic improvement of the kidney disease in the Col4A3 knockout mice treated with WT cells, from BM or blood source. A small amount of recovered ␣3␣4␣5(IV) protomer in the GBM could dramatically strengthen the structural integrity of the GBM type IV collagen network via the network interactions between ␣3␣4␣5(IV), ␣1␣2␣1(IV) and ␣5␣6␣5(IV) protomers, thus partly accounting for the concurrent increase in ␣5(IV) expression upon ␣3(IV) chain-mediated rescue.
Collectively, our studies demonstrated that multiple approaches of providing cells and stem cells to the Col4A3 knockout mice rescue the renal disease in these mice without the need for total body irradiation. The underlying mechanism for this cell-based therapy-cell transdifferentiation or cell fusion-remains unclear, and future studies are required to understand this phenomenon further. In addition, we demonstrated that simple blood transfusion is sufficient to provide therapeutic benefit in Col4A3 knockout mice and enable the production and incorporation of the missing type IV collagen chain. Moreover, it has not escaped our attention that such benefit via simple blood transfusion, if real, can be easily converted into a protocol for therapeutic testing in the clinic. Such efforts are ongoing in the laboratory, and future studies will also address whether simple blood transfusion can also benefit mice with diverse glomerular and tubular kidney diseases.
In conclusion, our work supports the development of a cellbased therapy for patients with Alport syndrome. Currently, therapies that can dramatically change the disease progression in patients with Alport syndrome are lacking. The experiments highlighted in this report offer hope for future potential cellbased therapy for our patients.
CONCISE METHODS
Mice
Generation and renal disease progression in Col4A3 knockout mice were previously described. 2, 8 The mice were backcrossed (more than 10 generations) into the C57BL/6 background. Col4A3 knockout mice were also maintained in the 129Sv background. Rag-1 KO, CD11bKO, and GFP ϩ transgenic C57BL/6 mice were purchased from Jackson Laboratory. All animals were housed under standard conditions in the Beth Israel Deaconess Medical Center animal facility. All animal studies were reviewed and approved by the Animal Care and Use Committee of the Beth Israel Deaconess Medical Center. For genotyping and BM genomic DNA PCR, see Supplemental Material and Methods.
BM Transplantation and BM Infusions
BM transplantation of 8-wk-old C57BL/6 Col4A3 knockout mice was performed as described previously. 11 BM transplantation of 129Sv Col4A3 knockout mice was performed as follows: Five-week-old mice were sublethally irradiated (total body irradiation, 8 Gy) and received a transplant of 10 6 unfractionated BM cells harvested from 129Sv or C57BL/6 WT and Col4A3 knockout donors. The 129Sv mice that received a transplant were killed at 10 wk of age, 5 wk after BM transplantation. BM infusions were given to nonirradiated, unconditioned 20-wk-old C57BL/6 Col4A3 knockout mice. Seven consecutive injections, twice weekly, of 10 7 BM cells from unconditioned Col4A3 knockout and GFP ϩ mice were given retro-orbitally. BM was harvested from donors as described previously. 11 We evaluated a cohort of 20-wk-old Col4A3 knockout littermates, at which point the mice presented with severe renal insufficiency, with one mouse dying from renal failure before treatment began at 19 wk of age. Treatment was completed at 23 wk of age. In the Col4A3 knockout mice treated with Col4A3 knockout BM, another mouse died from renal failure at 23.5 wk of age. All remaining mice were killed at 25 wk of age. For single BM infusion, 8-wk-old C57BL/6 Col4A3 knockout mice were systematically administered an injection of 10 7 unfractionated BM cells harvested from C57BL/6 WT and Col4A3 knockout donor. The mice were then killed at 20 wk of age, 12 wk after treatment.
For the survival study, 10 unconditioned, nonirradiated 22.5-wkold C57BL/6 Col4A3 knockout mice were administered an infusion of unfractionated 10 6 BM cells harvested from C57BL/6 Col4A3 knockout mice or WT mice that were Յ6 wk of age. Additional infusions were given at 23.5 and 24.5 wk.
Parabiotic Pairing and Blood Transfusions
Parabiotic pairing of 5-wk-old C57BL/6 WT and Col4A3 knockout mice was performed as described previously. 17 The parabiotic pair was sacrificed 6 wk after pairing. Blood transfusions were performed as follows: Eight-week-old C57BL/6 Col4A3 knockout mice received unfractionated blood from GFP ϩ donor mice. A total of 200 l of whole blood was injected retro-orbitally two to three times per week during the course of 3 wk. The recipients were then sacrificed at 12.5 wk of age. Next, 23.5-wk-old C57BL/6 Col4A3 knockout were administered retro-orbitally 200 l of whole blood harvested from healthy 6-wk-old Col4A3 knockout or GFP ϩ mice. After the treatment, two to three injections per week during the course of 3 wk, the mice were sacrificed at 25 and 27 wk of age or kept alive to monitor survival.
Human Kidney Tissue
Normal human kidney tissue was obtained from rejected kidney grafts and was provided by Dr. C. Shield, III, under appropriate patient consent and institutional approval.
ESC and Podocyte Cell Culture and Systemic Injection mESCs cells expressing GFP were a gift from Dr. George Daley (Children's Hospital, Boston, MA). Undifferentiated mESCs were cultured on primary mouse embryonic fibroblast feeder layer (Chemicon International, Temecula, CA) in DMEM (Life Technologies), supplemented with 15% FBS (Life Technologies), 1 M HEPES buffer (Sigma, St. Louis, MO), 100 mM sodium pyruvate (Sigma), 0.12% monothioglycerol (Sigma), and 1000 U/ml recombinant leukemia inhibitory factor (Chemicon). On the day of mESC injection, feeder cells were removed by incubation of the cell suspension twice with PBS for 30 min at 37°C, and single-cell mESCs, free from feeder fibroblasts, were resuspended in PBS for injection into KO mice. For differentiation, feeder cells were removed by incubation of the cell suspension twice with DMEM for 30 min at 37°C. mESCs were resuspended in culture medium lacking leukemia inhibitory factor. To induce embryoid body formation, mESCs were transferred to plastic Petri dishes to allow their aggregation and prevent adherence to the plate. The embryoid bodies were cultured for 5 d and then dissociated with trypsin, and single cells were resuspended in PBS for injection into KO mice. The trypsinized differentiated mESCs were also plated onto a type IV collagen-coated surface (0.1 mg/ml) for immunolabeling. Human ESCs (hESCs; approved H1 cell line) were purchased from WiCell International Stem Cell Bank (Madison, Wisconsin). Undifferentiated hESCs were propagated on irradiated mouse embryonic fibroblast feeder cell layer in DMEM F12 cell culture medium supplemented with 15% knockout FBS, 2 mM nonessential amino acids, 2 mM L-glutamine, 0.1 mM ␤-mercaptoethanol, and 10 ng/ml basic fibroblast growth factor. On the day of hESC injection, hESC colonies were dissociated from mouse embryonic fibroblast MEF feeder layer, and single-cell hESCs were resuspended in PBS for injection into COL4A3/Rag-1 DKO mice so as to give 1 to 2 million cells systematically per recipient.
Conditionally immortalized podocytes were a gift from Dr. Peter Mundel (Mt. Sinai School of Medicine, New York, NY) and were cultured as described previously. 18 In brief, cells were maintained in RPMI 1640 supplemented with 10% FCS, 100 U/ml penicillin, and 100 g/ml streptomycin in a humid atmosphere with 5% CO 2 . Under permissive conditions at 33°C and supplemented with 10 U/ml, IFN-␥ cells proliferate. Under nonpermissive conditions at 37°C and without IFN-␥, cells differentiate, expressing podocyte-specific markers. For differentiation, cells were passaged and then plated onto type I collagen-coated dishes (0.1 mg/ml) and allowed to differentiate for 12 to 14 d. The cells were trypsinized and resuspended in PBS for injection into KO mice or used for immunolabeling.
Eight-and 13-wk-old Col4A3 knockout mice were anesthetized by isoflurane inhalation and either 10 6 undifferentiated or differentiated mESCs or podocytes (permissive culture conditions at 33°C and supplemented with ␥-IFN) were injected retro-orbitally. Mice were killed at 12.5 and 21.0 wk of age, and tissues were collected for analyses.
RT-PCR
Kidneys were homogenized in TRIzol (Invitrogen) and extracted according to the manufacturer's directions. The purified RNA was digested with DNAseI (Invitrogen; according to the manufacturer's directions), and cDNA was synthesized using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems; according to the manufacturer's directions). The cDNA product was then digested with RNAseH (Invitrogen; according to the manufacturer's directions and using 10ϫ Promega PCR reaction buffer). The following primers (and product size) were used for the RT-PCR: ␤-Actin 5Ј-CGTGGGCCGCCCTAGGCACCA-3Ј and 5Ј-TTGGCCTTAGGGT-TCAGGGGGG-3Ј (200 bp), and COL4A3 5Ј-AAACGTGCACATG-GACAAGA-3Ј and 5Ј-CTCAGAGCCTGCACTTGTGA-3Ј (200 bp).
PCR reaction was 40 cycles at 95°C for 30s, 60°C for 30 s, and 72°C for 30 s. The PCR products were migrated by gel electrophoresis using 2% agarose gel in 1ϫ TAE. noresearch) were used at a 1:200 dilution. The slides were mounted with Vectashield Mounting Medium with DAPI (H1200; Vectashield) and glass coverslip and analyzed using the Axioskop 2 fluorescence microscope, AxioCam HRC camera, and Axiovision 4.3 software.
In Situ Hybridization for the Mouse Y-Chromosome (Fluorescence In Situ Hybridization Analysis)
Fluorescence in situ hybridization analysis for the mouse Y-chromosome in kidneys from gender-mismatched blood transfusion and male-derived mESCs injected into female COL4A3 KO recipients, as well as in cultured mESCs, was performed as described previously. 11 Urine Albumin, Urine Creatinine and Blood Urea Nitrogen (BUN) Measurements Urine samples were collected at the indicated times. Creatinine concentration was measured using the colorimetric assay Quantichrome (DICT-500) from BioAssays (Hayward, CA) according the manufacturer's directions, as well as using the colorimetric assay from Oxford Biomedical Research (Oxford, MI), also according to the manufacturer's directions. Albumin concentrations were measured using the Mouse Albuminuria ELISA (Bethyl Laboratory, Montgomery, TX) according to the manufacturer's directions. BUN levels were measured as described previously. 11, 16 Electron Microscopy
Electron microscopy analyses were performed as described previously. 11, 16 Immunoprecipitation Immunoprecipitation was performed as described previously. 2 For each immunoprecipitation sample, 100 g of extracted native NC1 hexamers containing solution in 500 l of extraction buffer (50 mM TRIS [pH7.5], 150 mM NaCl, and 1% Triton X100) with "Complete" Protease Inhibitor Cocktail (Roche) was incubated with 10 l of type IV collagen ␣3 chain antibody or anti-FLAG M2 antibody as a control (Sigma) overnight at 4°C under constant gentle rotation. Protein A/G Plus-Agarose beads (Santa Cruz Biotechnology, Santa Cruz, CA) were then added and incubated for 2 h at 4°C under constant gentle rotation. The beads were washed five times in 1 ml of extraction buffer, and bound proteins were eluted by boiling in 100 l of Laemmli buffer. Eluates were analyzed by SDS-PAGE and immunoblotting.
ECM Protein Extraction and Western Blot Analysis of Type IV Collagen Chain Expression
Kidney ECM proteins were prepared as described previously. 11 Briefly, kidneys were homogenized in PBS with proteinase inhibitors before DNAse I digestion in 1 M NaCl. The proteins were then incubated in 2% sodium deoxycholate and collagenase digested (Chromatographically purified collagenase, Worthington, NJ). Type IV collagen hexamers were found in the supernatant of the collagenase digest and were precipitated with 95% ethanol. Before Western blotting, the proteins were reduced and denatured in SDS-Laemmli buffer supplemented with 10% ␤-mercaptoethanol. Such treatment allows for the immunoblotting of NC1 type IV collagen monomers. Western blot analysis was performed as described previously 11 using 1:10,000 rabbit anti-mouse ␣3 or anti-mouse ␣4 antibodies in 5% milk in TBS-T.
Statistical Analysis
SEs were calculated, and t test and ANOVA were used to determine statistical differences. Bonferroni post hoc test was used after ANOVA. Kaplan-Meier curves were used for survival study, and the log-rank (Mantel-Cox) test was used to determine statistical significance. P Ͻ 0.05 was considered statistically significant.
